The estimated Net Worth of Kristen Yen is at least $7.39 Milion dollars as of 28 August 2024. Ms. Yen owns over 10,705 units of Soleno Therapeutics Inc stock worth over $4,108,556 and over the last 9 years she sold SLNO stock worth over $2,945,535. In addition, she makes $336,636 as Vice President - Clinical Operations at Soleno Therapeutics Inc.
Sign up
Ms. Yen SLNO stock SEC Form 4 insiders trading
Kristen has made over 8 trades of the Soleno Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 10,705 units of SLNO stock worth $507,738 on 28 August 2024.
The largest trade she's ever made was selling 37,829 units of Soleno Therapeutics Inc stock on 12 December 2023 worth over $1,412,535. On average, Kristen trades about 3,450 units every 12 days since 2016. As of 28 August 2024 she still owns at least 84,573 units of Soleno Therapeutics Inc stock.
You can see the complete history of Ms. Yen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kristen Yen biography
Kristen Yen serves as Vice President - Clinical Operations of the Company. Kristen Yen, MS. Ms. Yen has over 15 years of clinical research experience in the pharmaceutical and medical device industries. She joined the Company 2006, and currently serves as the head of Clinical Operations. Prior to joining the Company, she managed multiple U.S. and global clinical studies in oncology and held various positions of increasing responsibility at Titan Pharmaceuticals. She began her career in the industry as a clinical employee at PRA International. She has served as a team member and managed clinical studies in neonatology, neurology, pulmonary/allergy, cardiovascular disease, endocrine/metabolic disease, and oncology. She earned a Bachelor of Science degree in mathematics from the University of California, Davis, and a Master of Science degree in cell, molecular and neurosciences from the University of Hawaii, Manoa.
What is the salary of Kristen Yen?
As the Vice President - Clinical Operations of Soleno Therapeutics Inc, the total compensation of Kristen Yen at Soleno Therapeutics Inc is $336,636. There are 3 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.
How old is Kristen Yen?
Kristen Yen is 51, she's been the Vice President - Clinical Operations of Soleno Therapeutics Inc since 2006. There are 8 older and 1 younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.
What's Kristen Yen's mailing address?
Kristen's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Insiders trading at Soleno Therapeutics Inc
Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler a Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.
What does Soleno Therapeutics Inc do?
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
What does Soleno Therapeutics Inc's logo look like?
Complete history of Ms. Yen stock trades at Soleno Therapeutics Inc
Soleno Therapeutics Inc executives and stock owners
Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Anish Bhatnagar,
President, Chief Executive Officer, Director -
Dr. Anish Bhatnagar,
Pres, CEO, COO & Director -
Patricia Hirano,
Vice President - Regulatory Affairs -
Kristen Yen,
Vice President - Clinical Operations -
James H. MacKaness,
Chief Financial Officer -
Ernest Mario,
Independent Chairman of the Board -
William Harris,
Independent Director -
Gwen Melincoff,
Independent Director -
Birgitte Volck,
Independent Director -
Andrew Sinclair,
Independent Director -
Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
Sr. VP of Drug Devel. -
Anthony Wondka,
Sr. VP & GM -
Dawn Carter Bir,
-
Jack W Schuler,
-
Larry N Feinberg,
10% owner -
Opportunity, Llc Vivo Oppor...,
-
Jonathan Wolter,
Chief Financial Officer -
Stephen Kirnon,
Director -
Mahendra Shah,
Director -
Rajen Dalal,
Director -
Edgar Engleman,
Director -
Ventures V, Llc Vivo,
10% owner -
Steinar J Engelsen,
Director -
James Walter Glasheen,
Director -
Stuart J Collinson,
Director -
Ventures V, Llc Vivo Ventur...,
-
Raymond W. Urbanski,
CHIEF DEVELOPMENT OFFICER -
Management Vii Llctechnolog...,
-
Mangement Llcbioasia Invest...,
-
Larry Noracle Partners Lp F...,
-
Llp Abingworth,
10% owner -
Ventures V, Llc Vivo Ventur...,
-
Group Inc.Carlyle Holdings ...,
-
Meredith Manning,
Chief Commercial Officer -
Michael F. Huang,
Sr. VP of Clinical Development -
Matthew Pauls,
-
Group Inc.Carlyle Holdings ...,
-
Advisors Llcperceptive Life...,
-
James H Mackaness,
CHIEF FINANCIAL OFFICER